Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4327-4330

  Chen, Tao ^a   Yi, Shang Hui ^b   Liu, Xiao Yu ^a   Liu, Zhi Gang ^a  

^a Shenzhen University School of Medicine   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Analysis; MDM2; Meta; Polymorphism; Prostate cancer risk

Indexed keywords

EID: 84874005262     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4327     Document Type: Article

References (20)

1. Boersma BJ, Howe TM, Goodman JE, et al (2006). Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst, 98, 911-9.
2. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
3. Bond GL, Hu W, Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4.
4. Bouska A & Eischen CM (2009). Mdm2 affects genome stability independent of p53. Cancer Res, 69, 1697-701.
5. Detchokul S & Frauman AG (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol, 71, 157-74.
6. Eischen CM & Lozano G (2009). p53 and MDM2: antagonists or partners in crime. Cancer Cell, 15, 161-2.
7. Jaboin JJ, Hwang M, Perez CA, et al (2011). No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol, 29, 319-23.
8. Kibel AS, Jin CH, Klim A, et al (2008). Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate, 68, 1179-86.
9. Kruse JP & Gu W (2009) Modes of p53 regulation. Cell, 137, 609-22.
10. Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
11. Ma H, Hu Z, Zhai X, et al (2006). Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett, 240, 261-7.
12. Ma HB, Huang T, Han F, et al (2012). Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6.
13. Mandal RK, Mittal RD (2010). Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population. Urol Oncol, 30, 555-61.
14. Nunobiki O, Ueda M, Yamamoto M, et al (2010). MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol, 118, 258-61.
15. Ohmiya N, Taguchi A, Mabuchi N, et al (2006). MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40.
16. Stoehr R, Hitzenbichler F, Kneitz B, et al (2008). Mdm2- SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer, 99, 78-82.
17. Sun T, Lee GS, Oh WK, et al (2010). Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res, 16, 5244-51.
18. Vassilev LT, Vu BT, Graves B, et al (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-8.
19. Xu B, Xu Z, Cheng G, et al (2010). Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet, 202, 76-81.
20. Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6.